Langerhans' cell histiocytosis (LCH) (previously histiocytosis X) is an infrequent disease with protean clinical manifestations and an unpredictable course. The role of radiotherapy in the soft tissue complications of LCH was evaluated in this retrospective study of 40 patients seen in two major Phi
Mitotic histiocytes and intranuclear Langerhans cell granules in histiocytosis X
β Scribed by Mikihiro Shamoto
- Book ID
- 105643671
- Publisher
- Springer-Verlag
- Year
- 1977
- Tongue
- English
- Weight
- 923 KB
- Volume
- 24
- Category
- Article
- ISSN
- 0340-6075
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Six children received etoposide as the single agent for treatment of Langerhans cell histiocytosis (LCH; histiocytosis X). Five were less than 2 years old at diagnosis. All had multiorgan involvement; one had liver and pulmonary dysfunction. Two infants also had clinical signs of immune deficiency.
Viana et al. [I] described their experience with etoposide (VP-16) as initial therapy in the management of patients with Langerhans cell histiocytosis (LCH). However, caution should be used in advocating the use of an epipodophyllotoxin as the "drug of choice" for the treatment of this disorder. Alt
for the Histiocyte Society Background. Previous reports have suggested activity of the nucleoside analogues 2-chlorodeoxyadenosine (2-CdA) and 2Πdeoxycoformycin (2Π-DCF) in Langerhans cell histiocytosis (LCH). Procedure. To assess the efficacy of 2-CdA and 2Π-DCF as salvage therapy for LCH, a survey